BTMD vs. ADTH, DCRD, OPAL, TLRY, CRON, USNA, CGC, MNMD, ACB, and CDXC
Should you be buying biote stock or one of its competitors? The main competitors of biote include AdTheorent (ADTH), Decarbonization Plus Acquisition Co. IV (DCRD), OPAL Fuels (OPAL), Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), Aurora Cannabis (ACB), and ChromaDex (CDXC).
biote (NASDAQ:BTMD) and AdTheorent (NASDAQ:ADTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
biote has higher revenue and earnings than AdTheorent. AdTheorent is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
In the previous week, biote and biote both had 1 articles in the media. AdTheorent's average media sentiment score of 1.84 beat biote's score of 1.67 indicating that AdTheorent is being referred to more favorably in the news media.
biote currently has a consensus price target of $8.11, suggesting a potential upside of 21.23%. AdTheorent has a consensus price target of $4.69, suggesting a potential upside of 46.94%. Given AdTheorent's higher probable upside, analysts clearly believe AdTheorent is more favorable than biote.
AdTheorent received 13 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 61.90% of users gave AdTheorent an outperform vote.
biote has a net margin of 4.30% compared to AdTheorent's net margin of -2.67%. AdTheorent's return on equity of 0.77% beat biote's return on equity.
biote has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, AdTheorent has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.
21.7% of biote shares are owned by institutional investors. Comparatively, 37.7% of AdTheorent shares are owned by institutional investors. 13.9% of biote shares are owned by insiders. Comparatively, 7.1% of AdTheorent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
biote beats AdTheorent on 11 of the 17 factors compared between the two stocks.
Get biote News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
